MX2018014129A - Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato. - Google Patents

Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.

Info

Publication number
MX2018014129A
MX2018014129A MX2018014129A MX2018014129A MX2018014129A MX 2018014129 A MX2018014129 A MX 2018014129A MX 2018014129 A MX2018014129 A MX 2018014129A MX 2018014129 A MX2018014129 A MX 2018014129A MX 2018014129 A MX2018014129 A MX 2018014129A
Authority
MX
Mexico
Prior art keywords
eteplirsen
pharmaceutical composition
subject
administering
treating
Prior art date
Application number
MX2018014129A
Other languages
English (en)
Inventor
Holt Thomas
Original Assignee
Sarepta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sarepta Therapeutics Inc filed Critical Sarepta Therapeutics Inc
Publication of MX2018014129A publication Critical patent/MX2018014129A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis

Abstract

La presente invención se refiere a composiciones farmacéuticas que comprenden Eteplirsen; en la presente también se proporcionan métodos para tratar una enfermedad muscular en un sujeto en necesidad de los mismos, que comprende administrar al sujeto una composición farmacéutica de la descripción.
MX2018014129A 2016-05-24 2017-05-24 Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato. MX2018014129A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662340947P 2016-05-24 2016-05-24
US201662429160P 2016-12-02 2016-12-02
PCT/US2017/034265 WO2017213854A1 (en) 2016-05-24 2017-05-24 Pharmaceutical composition comprising eteplirsen

Publications (1)

Publication Number Publication Date
MX2018014129A true MX2018014129A (es) 2019-04-29

Family

ID=59093599

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018014129A MX2018014129A (es) 2016-05-24 2017-05-24 Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.

Country Status (15)

Country Link
US (1) US20190275072A1 (es)
EP (1) EP3463390A1 (es)
JP (1) JP2019516730A (es)
KR (1) KR20190009343A (es)
CN (1) CN109562123A (es)
AU (1) AU2017278699A1 (es)
BR (1) BR112018074299A2 (es)
CA (1) CA3024178A1 (es)
CO (1) CO2018013828A2 (es)
IL (1) IL263040A (es)
MA (1) MA45158A (es)
MX (1) MX2018014129A (es)
SG (1) SG11201809494VA (es)
TW (1) TW201805002A (es)
WO (1) WO2017213854A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI541024B (zh) 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
EP4219717A3 (en) * 2018-06-13 2023-12-20 Sarepta Therapeutics, Inc. Exon skipping oligomers for muscular dystrophy
WO2019241385A2 (en) * 2018-06-13 2019-12-19 Sarepta Therapeutics, Inc. Exon skipping oligomers for muscular dystropy
JP2021526807A (ja) * 2018-06-14 2021-10-11 サレプタ セラピューティクス， インコーポレイテッド 筋ジストロフィーに対するエクソンスキッピングオリゴマーおよびオリゴマーコンジュゲート

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3650699T2 (de) 1985-03-15 1999-04-15 Antivirals Inc Immunotestmittel für Polynukleotid und Verfahren
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5521063A (en) 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
CA1339987C (en) 1988-09-01 1998-08-04 Robert Bruce Merrifield Peptide synthesis method and solid support for use in the method
US7807816B2 (en) 2004-06-28 2010-10-05 University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
US8299206B2 (en) 2007-11-15 2012-10-30 Avi Biopharma, Inc. Method of synthesis of morpholino oligomers
CA2884340C (en) 2007-11-15 2017-07-25 Sarepta Therapeutics, Inc. Method of synthesis of morpholino oligomers
US8076476B2 (en) 2007-11-15 2011-12-13 Avi Biopharma, Inc. Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits
RS55610B1 (sr) 2010-09-30 2017-06-30 Nippon Shinyaku Co Ltd Derivat morfolino nukleinske kiseline
AU2012345638C1 (en) 2011-11-30 2018-10-18 Sarepta Therapeutics, Inc. Induced exon inclusion in spinal muscle atrophy
CN103933549A (zh) * 2013-01-17 2014-07-23 刘海俊 一种新的血管抑素滴眼剂及其制备方法
CA2906812A1 (en) * 2013-03-15 2014-09-18 Sarepta Therapeutics, Inc. Improved compositions for treating muscular dystrophy

Also Published As

Publication number Publication date
US20190275072A1 (en) 2019-09-12
CA3024178A1 (en) 2017-12-14
JP2019516730A (ja) 2019-06-20
BR112018074299A2 (pt) 2019-03-12
KR20190009343A (ko) 2019-01-28
CN109562123A (zh) 2019-04-02
EP3463390A1 (en) 2019-04-10
IL263040A (en) 2018-12-31
AU2017278699A1 (en) 2018-11-15
SG11201809494VA (en) 2018-12-28
WO2017213854A1 (en) 2017-12-14
MA45158A (fr) 2019-04-10
TW201805002A (zh) 2018-02-16
CO2018013828A2 (es) 2018-12-28

Similar Documents

Publication Publication Date Title
MX2021009673A (es) Moduladores de ror-gamma.
PH12016501966B1 (en) Compounds and compositions as toll-like receptor 7 agonists
MX2017005834A (es) Polinucleotidos aad para el tratamiento de la enfermedad de parkinson.
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
TW201613901A (en) New compounds
MD4733B1 (ro) Anticorpi anti-TIGIT
EA201790273A1 (ru) Флагеллиновые композиции и их применение
MX2017005236A (es) Profarmacos de carbidopa y l-dopa y metodos de uso.
PH12018500315A1 (en) Fumagillol heterocyclic compounds and methods of making and using same
MX2017002816A (es) Derivados de pirazolopiridina y su uso en terapia.
PH12019501018A1 (en) Pharmaceutical composition, methods for treating and uses thereof
WO2015171558A3 (en) BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
MX2017006464A (es) Combinaciones de inhibidor de tlr e inhibidor de tirosina cinasa de bruton.
EA201691918A1 (ru) Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения
MX2017006437A (es) Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor.
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
PH12016502243A1 (en) Pharmaceutical compositions for treating infectious diseases
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
MY186134A (en) Curcumin-peptide conjugates and formulations thereof
MX2019001634A (es) Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos.
MX2017012022A (es) Compuestos organicos.
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.
MX2017009608A (es) Compuestos anticancerigenos.